Press

Fount Therapeutics, LLC is a sustainable drug discovery enterprise with a proven team of R & D talent that has created multiple launched medicines.

06.12.2018

Fount Therapeutics, LLC is a sustainable drug discovery enterprise with a proven team of R & D talent that has created multiple launched medicines. Fount is maturing three newco subsidiaries: Kinnate Biopharma, Inc. (Oncology), Immanate Therapeutics, Inc. (Immunology & Immuno-Oncology), and Audere Medicines, Inc. (theme undisclosed). Continue

G1 Therapeutics Announces Expansion of Development Programs

01.10.2017

G1 Therapeutics announced today the expansion of its pipeline of novel cancer therapies with initiation of three development programs in breast cancer. G1 is enrolling a Phase 2 study of its intravenous CDK4/6 inhibitor trilaciclib for the treatment of triple-negative breast cancer (TNBC), and a Phase 1b/2a study of its oral CDK4/6 inhibitor G1T38 for the treatment of ER+, HER2-... Continue